A pilot study of the teratogenicity of vagus nerve stimulation in a rabbit model

Brain Stimulation

Volumn 2, Issue 1, 2009, Pages 41-49

  Danielsson, Ingela ^a   Lister, Laurence ^b  

^a Cyberonics Inc   (Italy)

^b Toxikon Corporation   (United States)

Author keywords

birth defects; pregnancy; teratogenicity; vagus nerve stimulation; VNS

Indexed keywords

ANALYSIS OF VARIANCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; BIRTH; BRAIN DISEASE; CLINICAL OBSERVATION; CONTROLLED STUDY; COPULATION; DEPRESSION; DEVICE; EPILEPSY; FEMALE; FERTILITY; FETUS; FLUID INTAKE; FOOD INTAKE; HISTOPATHOLOGY; MALE; MATING; NERVE STIMULATION; NEWBORN MORBIDITY; NONHUMAN; ORGAN WEIGHT; PILOT STUDY; PREGNANCY; PRIORITY JOURNAL; RABBIT; RANDOMIZATION; SAMPLE SIZE; SKELETON MALFORMATION; SOFT TISSUE DISEASE; STATISTICAL SIGNIFICANCE; SURVIVAL; TERATOGENICITY; UTERUS; VAGUS NERVE STIMULATION; WEIGHT; ANIMAL; ELECTRODE IMPLANT; HUMAN; PHYSIOLOGY; PRENATAL EXPOSURE;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

ANIMALS; DEPRESSION; ELECTRODES, IMPLANTED; EPILEPSY; FEMALE; FERTILITY; FETUS; HUMANS; MALE; PILOT PROJECTS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RABBITS; RANDOM ALLOCATION; VAGUS NERVE STIMULATION;

EID: 58249092785     PISSN: 1935861X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brs.2008.06.008     Document Type: Article

References (39)

1. A North American Registry for Epilepsy and Pregnancy, a unique public/private partnership of health surveillance. Epilepsia 39 (1998) 793-798
2. Kanner A.M. Depression in epilepsy: a frequently neglected multifaceted disorder. Epilepsy Behav 4 Suppl4 (2003) S11-S19
3. Wrench J., Wilson S.J., and Bladin P.F. Mood disturbance before and after seizure surgery: a comparison of temporal and extratemporal resections. Epilepsia 45 (2004) 534-543
4. Gilliam F.G., Mendiratta A., Pack A.M., and Bazil C.W. Epilepsy and common comorbidities: improving the outpatient epilepsy encounter. Epileptic Disord 7 Suppl1 (2005) S27-S33
5. Ornoy A. Neuroteratogens in man: an overview with special emphasis on the teratogenicity of antiepileptic drugs in pregnancy. Reprod Toxicol 22 (2006) 214-226
6. Lateef T.M., and Nelson K.B. In utero exposure to antiepileptic drugs: teratogenicity and neonatal morbidity. Curr Neurol Neurosci Rep 7 (2007) 133-138
7. Marchi N.S., Azoubel R., and Tognola W.A. Teratogenic effects of lamotrigine on rat fetal brain: a morphometric study. Arq Neuropsiquiatr 59 (2001) 362-364
8. ten Berg K., Samrén E.B., van Oppen A.C., Engelsman M., and Lindhout D. Levetiracetam use and pregnancy outcome. Reprod Toxicol 20 (2005) 175-178
9. Louik C., Lin A.E., Werler M.M., Hernández-Díaz S., and Mitchell A.A. First-trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects. N Engl J Med 356 (2007) 2675-2683
10. Way C.M. Safety of newer antidepressants in pregnancy. Pharmacotherapy 27 (2007) 546-552
11. Suri R., Altshuler L., Hellemann G., et al. Effects of antenatal depression and antidepressant treatment on gestational age at birth and risk of preterm birth. Am J Psychiatry 164 (2007) 1206-1213
12. DeBattista C., Cochran M., Barry J.J., and Brock-Utne J.G. Fetal heart rate decelerations during ECT-induced seizures: is it important?. Acta Anaesthesiol Scand 47 (2003) 101-103
13. Physician'sManual, VNS Therapy Pulse Model 102 Generator and VNS Therapy Pulse Duo Model 102R Generator. Available at: http://www.vnstherapy.com/manuals/index.asp?type=vns-hcp%2fep. Accessed on: March 12, 2008.
14. Henry T.R. Therapeutic mechanisms of vagus nerve stimulation. Neurology 59 Suppl. 4 (2002) S3-S14
15. Morris III G.L., and Mueller W.M. Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. The Vagus Nerve Stimulation Study Group E01-E05. Neurology 53 (1999) 1731-1735
16. In: Richardson V. (Ed). Rabbbits Health Husbandry & Diseases (2000), Blackwell Science Ltd, Malden, MA
17. Harcourt-Brown F. Textbook of Rabbit Medicine. Woburn, MA:Butterworth Heinemann (2002)
18. Azziz R., Woods K.S., Reyna R., et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89 (2004) 2745-2749
19. Morrell M.J. Reproductive and metabolic disorders in women with epilepsy. Epilepsia 44 Suppl.4 (2003) S11-S20
20. Lossius M.I., Taubøll E., Mowinckel P., Mørkrid L., and Gjerstad L. Reversible effects of antiepileptic drugs on reproductive endocrine function in men and women with epilepsy-a prospective randomized double-blind withdrawal study. Epilepsia 48 (2007) 1875-1882
21. Harden C.L., and Leppik I. Optimizing therapy of seizures in women who use oral contraceptives. Neurology 67 12 Suppl. 4 (2006) S56-S58
22. Holmes L.B., Wyszynski D.F., and Lieberman E. The AED (antiepileptic drug) pregnancy registry: a 6-year experience. Arch Neurol 61 (2004) 673-678
23. Wyszynski D.F., Nambisan M., Surve T., et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 22 (2005) 961-965
24. Wide K., Winbladh B., and Källén B. Major malformations in infants exposed to antiepileptic drugs in utero, with emphasis on carbamazepine and valproic acid: a nation-wide, population-based register study. Acta Paediatr 93 (2004) 174-176
25. Morrow J., Russell A., Guthrie E., et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. J Neurol Neurosurg Psychiatry 77 (2006) 193-198
26. Meador K.J., Baker G.A., Finnell R.H., et al. In utero antiepileptic drug exposure: fetal death and malformations. Neurology 67 (2006) 407-412
27. Oyen N., Vollset S.E., Eide M.G., Bjerkedal T., and Skjaerven R. Maternal epilepsy and offsprings' adult intelligence: a population-based study from Norway. Epilepsia 48 (2007) 1731-1738
28. Yerby M., Koepsell T., and Daling J. Pregnancy complications and outcomes in a cohort of women with epilepsy. Epilepsia 26 (1985) 631-635
29. Information for healthcare professionals Lamotrigene (marketed as Lamictal). FDA Alert [9/2006]. US Food and Drug Administration Center for Drug Evaluation and Research. Available at: http://www.fda.gov/CDER/drug/InfoSheets/HCP/lamotrigineHCP.htm. Last accessed: March 12, 2008.
30. Hirschfeld R.M., Calabrese J.R., Weissman M.M., et al. Screening for bipolar disorder in the community. J Clin Psychiatry 64 (2003) 53-59
31. Runnström J. An analysis of the action of lithium on sea urchin development. Biolog Bull 68 (1935) 378-384
32. Yonkers K.A., Wisner K.L., Stowe Z., et al. Management of bipolar disorder during pregnancy and the postpartum period. Am J Psychiatry 161 (2004) 608-620
33. Newport D.J., Calamaras M.R., DeVane C.L., et al. Atypical antipsychotic administration during late pregnancy: placental passage and obstetrical outcomes. Am J. Psychiatry 164 (2007) 1214-1220
34. Eberhard-Gran M., Eskild A., and Opjordsmoen S. Use of psychotropic medications in treating mood disorders during lactation: practical recommendations. CNS Drugs (2006) 187-198
35. Alwan S., Reefhuis J., Rasmussen S.A., et al. Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects. N Engl J Med 28 (2007) 2684-2692
36. Pinette M.G., Santarpio C., Wax J.R., and Blackstone J. Electroconvulsive therapy in pregnancy. Obstet Gynecol 110 (2007) 465-466
37. Husain M.M., Stegman D., and Trevino K. Pregnancy and delivery while receiving vagus nerve stimulation for the treatment of major depression: a case report. Ann Gen Psychiatry 4 (2005) 16
38. Brent R.L. Utilization of animal studies to determine the effects and human risks of environmental toxicants (drugs, chemicals, and physical agents). Pediatrics 113 (2004) 984-995
39. Rush A.J., Sackeim H.A., Marangell L.B., et al. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry 58 (2005) 355-363